Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108758 · ClinicalTrials.gov registry record · Phase 2
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
A Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 20
- Study locations
NCT00108758 is a Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors that has completed, run by Novo Nordisk A/S. The registered enrollment target is 23 participants, below the 136-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00108758, a Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Conditions Studied
Interventions
- DRUG activated recombinant human factor VII
Study Locations (20)
Other
- Novo Nordisk Investigational Site - Ciudad Autónoma de Bs. As.
- Novo Nordisk Investigational Site - Belo Horizonte
- Novo Nordisk Investigational Site - Recife
- Novo Nordisk Investigational Site - Ribeirão Preto
- Novo Nordisk Investigational Site - Sofia
California
- Novo Nordisk Investigational Site - Berkeley
- Novo Nordisk Investigational Site - Los Angeles
Pennsylvania
- Novo Nordisk Investigational Site - Philadelphia
- Novo Nordisk Investigational Site - Philadelphia
Illinois
- Novo Nordisk Investigational Site - Chicago
Indiana
- Novo Nordisk Investigational Site - Indianapolis
Iowa
- Novo Nordisk Investigational Site - Iowa City
Louisiana
- Novo Nordisk Investigational Site - New Orleans
Massachusetts
- Novo Nordisk Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108758
The ClinicalTrials.gov registry entry for NCT00108758 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (83% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT00108758 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00108758 about?
NCT00108758 is a clinical study titled "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia". This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
What is the current status of trial NCT00108758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-03. Estimated completion is 2005-11.
What conditions does trial NCT00108758 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors.
What interventions are being tested in trial NCT00108758?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT00108758?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108758 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
COMPLETED
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
COMPLETED · Phase 3
-
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
COMPLETED · Phase 3
-
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
COMPLETED · Phase 1
Explore more on PlainTrial
Congenital Bleeding Disorder
All registered trials for this condition
Haemophilia A With Inhibitors
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.